Detroit, MI 的 急性髓系白血病 臨床試驗
14 項針對 急性髓系白血病 的研究正在 Detroit（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
招募中3 期
- Henry Ford Health System, Detroit
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
招募中2 期
- Henry Ford Hospital, Detroit
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
招募中2 期
- Wayne State University/Karmanos Cancer Institute, Detroit
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Children's Hospital of Michigan, Detroit
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
招募中3 期
- Children's Hospital of Michigan, Detroit
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
招募中3 期
- Wayne State University School of Medicine, Detroit
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
招募中1 期
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer Institute, Detroit
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
招募中3 期
- Henry Ford Cancer Institute, Detroit
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中觀察性研究
- Children's Hospital of Michigan, Detroit
- Henry Ford Health System, Detroit
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
招募中2 期
- Karmanos Cancer Institute, Detroit
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
招募中1 期
- Karmanos Cancer Institute, Detroit
HPC Offered for PRESERVE Expansion
招募中觀察性研究
- Henry Ford Health, Detroit
其他城市的 急性髓系白血病 試驗
- Houston, TX85 項研究
- New York City, NY51 項研究
- Boston, MA44 項研究
- Seattle, WA41 項研究
- Baldwin Park, CA40 項研究
- Columbus, OH35 項研究
- Philadelphia, PA34 項研究
- Durham, NC33 項研究
- Atlanta, GA31 項研究
- Tampa, FL29 項研究
- Chicago, IL26 項研究
- Portland, OR25 項研究
Detroit 的其他研究
- 非小細胞肺癌44 項研究
- 乳癌33 項研究
- 癌症（所有類型）29 項研究
- 大腸直腸癌26 項研究
- 卵巢癌26 項研究
- 轉移性癌症24 項研究
- 前列腺癌22 項研究
- 子宮內膜癌21 項研究
- 肺癌20 項研究
- 多發性骨髓瘤19 項研究
- 胃癌16 項研究
- 頭頸部鱗狀細胞癌15 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。